comprehensive -WSS

comprehensive

author：fashion 2025-09-28 02:47:39 - browse：5297

Geoff Martha, CEO of Medtronic Courtesy Medtronic

As one of the largest and oldest medical device companies in the world, Medtronic has a foot in almost every clinical area.

The device maker with a market valuation of nearly $100 billion sells pacemakers, spinal cord stimulators, stents, monitors. Name a device, and they probably make it. The behemoth is ubiquitous in health care, but its size can make innovation sluggish. Medtronic has tried to become more streamlined in recent years — the company announced plans last year to spin off its patient monitoring and respiratory businesses, which Reuters recently reported, citing unnamed sources, may go to the Carlyle Group, a private equity firm.

Still, the device giant is immersed in many different specialties, including diabetes and high blood pressure, where the company has experienced some setbacks. Medtronic has sold old-school insulin pumps since the 1980s and therefore developed robust dosing algorithms, but has never successfully built a tubeless pump. The company plans to buy Korean patch pump maker EOFlow, but EOFlow is enmeshed in a patent battle with Insulet. A federal judge blocked EOFlow from selling its wearable patch pumps earlier this month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout Newsletter: Geron, Novo Nordisk, WuXi updates

leisure time

WSS

Commercial surrogacy can be ethical, despite pope’s claims

Colonoscopy prep: Liquid

Gene editing the human germline: What are the risks?

Plastic surgeons increase patient psychiatric screenings

U.K. researchers warn about biases in medical devices, algorithms

Apple Vision Pro: A first look at health apps on the new VR headset

hotspot

comprehensive

explore

Hollywood unions extend contract negotiations for actors

SAMSHA loosens regulations on methadone treatment centers

Dobbs anniversary: the lost opportunity of abortion as health care

Gene editing the human germline: What are the risks?

BioMarin wins approval for gene therapy to treat hemophilia A

Positive childhood experiences can help future health

Affirmative action in medical school literally saved lives

SAMSHA loosens regulations on methadone treatment centers

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Positive childhood experiences can help future health

hotspot

Neuroscience’s long legacy of racism

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Stop the failed accountable care organization experiment

What we need to know about Arena Bioworks

Vertigo drug brings hope for rare neuron disorder, Niemann

hotspot

leisure time

explore

Wikipedia